Press Releases

Press Releases

January 14, 2016
Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.
April 18, 2016
Quanterix announces the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Lab is a dedicated laboratory environment for custom assay development and clinical sample testing. 
November 15, 2016
Researchers will present key findings on the development of sensitive predictive biomarkers to establish therapeutic strategies for neurodegenerative diseases; Company will join forces with UmanDiagnostics to provide an ultrasensitive assay for Nf-L
May 16, 2017
CEO to discuss promising role of protein biomarkers in advancing detection and treatment of traumatic brain injury
Business Wire
Discussion will be led by Dr. Edward Wild and Lauren Byrne from the UCL Institute of Neurology, with introductory remarks from Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
DENVER – A new test could reliably detect early increases in prostate specific antigen (PSA) levels – a biomarker commonly used to measure the recurrence of prostate cancer – in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow men with…
CAMBRIDGE, MA – July 21, 2011 – Quanterix Corporation, an in vitro diagnostics (IVD) company providing life science researchers and IVD labs single molecule technology with unprecedented sensitivity and precision, announced that the analytical performance of AccuPSA™, a fifth–generation digital…
CAMBRIDGE, MA – January 5, 2012 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today a strategic investment and technology development agreement with In–Q–Tel (IQT), the…
LEXINGTON, Mass., July 30, 2013 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today unveiled its Single Molecule Array (Simoa) technology at the 2013 AACC Annual Meeting in Houston, Texas,…
Lexington, Mass. – March 14, 2014 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that JAMA Neurology has published a ground-breaking study in which its Simoa (single molecule…